Avid followers on investing legend Warren Buffett will be familiar with his saying that:

“You pay a very high price in the stock market for a cheery consensus”

Buffett’s point is that ‘investing with the herd’ can be a very dangerous pursuit!

Many investors are much more comfortable buying shares which are popular, doing well and which everyone seems to rate as a buy.

This scenario can ultimately be a major source of long-term portfolio underperformance. This occurs because rarely is an undervalued stock (let alone a bargain) to be found amongst the most sought after, popular and widely bought companies.

Shares in CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC) are both trading near their all-time highs and on trailing price-to-earnings multiples of 27x and 34x respectively.

Despite both companies being high quality businesses with superb track records and positive future outlooks, in my view, Buffett probably wouldn’t be a buyer of either CSL or Ramsay at these levels.

In fact, he hasn’t even been a buyer of these two companies at lower levels (to the best of our knowledge) despite every possibility that he is familiar with the financial details of these global operators.

In respect of CSL, I’d be guessing that Buffett would consider CSL outside his “circle of competence”. Despite the impressive track record of this world-class biotech, Buffett would probably view the future market dynamics for CSL (I’m talking time frames of 10, 20 and 30 years) as too difficult to accurately estimate. This means he would consider it too difficult to accurately estimate CSL’s future earnings stream and hence its value.

With regards to Ramsay, the dependable nature of the group’s earnings base would no doubt appeal to Buffett, however while he happily pays up for quality, he has rarely been comfortable purchasing stocks at very high multiples. He prefers to base his investment case on current maintainable earnings rather than future expectations. That likely rules out Ramsay Health Care.

3 Better Bets Than CSL and Ramsay Health Care

Discover The Motley Fool's top 3 blue chips for 2016. These 3 'new breed' shares pay fully franked dividends AND offer the very real prospect of significant capital appreciation. Simply click here to gain access to this comprehensive FREE investment report.

No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tim McArthur has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.